IRIS Institutional Research Information System - OPENBS Open Archive UniBS

PECORELLI, Sergio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.331
AS - Asia 4.955
EU - Europa 4.353
SA - Sud America 992
AF - Africa 90
Continente sconosciuto - Info sul continente non disponibili 16
OC - Oceania 13
AN - Antartide 1
Totale 23.751
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.169
CN - Cina 1.948
SG - Singapore 1.458
UA - Ucraina 1.308
BR - Brasile 837
IT - Italia 635
DE - Germania 615
HK - Hong Kong 561
PL - Polonia 426
FI - Finlandia 386
VN - Vietnam 288
GB - Regno Unito 230
TR - Turchia 202
IE - Irlanda 194
RU - Federazione Russa 180
IN - India 174
FR - Francia 129
CA - Canada 108
SE - Svezia 76
BD - Bangladesh 68
AR - Argentina 59
IQ - Iraq 37
MX - Messico 37
JP - Giappone 33
NL - Olanda 31
ZA - Sudafrica 31
ID - Indonesia 29
EC - Ecuador 28
ES - Italia 25
EE - Estonia 24
SA - Arabia Saudita 23
VE - Venezuela 22
AT - Austria 19
BE - Belgio 19
MU - Mauritius 18
LT - Lituania 17
EU - Europa 16
PK - Pakistan 14
AE - Emirati Arabi Uniti 13
MA - Marocco 13
UZ - Uzbekistan 13
AU - Australia 12
IR - Iran 12
CL - Cile 11
CZ - Repubblica Ceca 11
PY - Paraguay 11
UY - Uruguay 10
IL - Israele 9
NP - Nepal 9
CO - Colombia 8
AZ - Azerbaigian 7
KG - Kirghizistan 7
KR - Corea 7
EG - Egitto 6
JO - Giordania 6
KE - Kenya 6
KZ - Kazakistan 6
TN - Tunisia 6
BH - Bahrain 4
CR - Costa Rica 4
DZ - Algeria 4
JM - Giamaica 4
LK - Sri Lanka 4
PE - Perù 4
PS - Palestinian Territory 4
PT - Portogallo 4
TW - Taiwan 4
AL - Albania 3
BB - Barbados 3
BG - Bulgaria 3
CH - Svizzera 3
GE - Georgia 3
GR - Grecia 3
LU - Lussemburgo 3
BO - Bolivia 2
BY - Bielorussia 2
LB - Libano 2
LV - Lettonia 2
TH - Thailandia 2
AO - Angola 1
AQ - Antartide 1
BW - Botswana 1
CY - Cipro 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
GA - Gabon 1
GT - Guatemala 1
HN - Honduras 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
MD - Moldavia 1
MQ - Martinica 1
MS - Montserrat 1
MY - Malesia 1
NG - Nigeria 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
OM - Oman 1
PH - Filippine 1
QA - Qatar 1
Totale 23.745
Salva come PNG Salva come JPEG
Città #
Fairfield 1.663
Woodbridge 1.636
Ashburn 1.123
Houston 1.123
Jacksonville 916
Ann Arbor 800
Wilmington 764
Singapore 703
Seattle 702
Cambridge 645
Hong Kong 541
Warsaw 419
Beijing 367
Chandler 364
Nanjing 353
Princeton 353
New York 304
Dearborn 212
Los Angeles 211
Dublin 194
Helsinki 171
Istanbul 161
Nanchang 128
Des Moines 117
Ho Chi Minh City 112
Moscow 100
San Diego 90
The Dalles 88
Shenyang 87
São Paulo 79
Changsha 76
Munich 72
Shanghai 70
Buffalo 67
Hebei 67
Kunming 67
Milan 66
San Francisco 63
Jinan 60
Jiaxing 59
Hanoi 58
Redondo Beach 58
Tianjin 55
Chicago 53
Toronto 52
Brescia 47
Hangzhou 43
London 40
Dallas 31
Verona 30
Turku 29
Indianapolis 28
Santa Clara 28
Montreal 27
Tokyo 27
Zhengzhou 27
Chennai 25
Ningbo 25
Rio de Janeiro 24
Tallinn 24
Denver 23
Orem 23
Belo Horizonte 22
Hefei 21
Rome 21
Brasília 20
Lanzhou 20
Monmouth Junction 20
Brussels 19
Lancaster 19
Stockholm 19
Washington 19
Brooklyn 18
Guangzhou 18
Taizhou 18
Poplar 17
Porto Alegre 17
Pune 17
Charlotte 16
Dong Ket 16
Norwalk 16
Orange 16
Atlanta 15
Johannesburg 15
Nuremberg 15
Phoenix 15
Amsterdam 14
Boston 14
Central 14
Dhaka 14
Mexico City 14
Mumbai 14
Guarulhos 13
Taiyuan 13
Haiphong 12
Campinas 11
Manchester 11
Quito 11
Fuzhou 10
Riyadh 10
Totale 16.574
Salva come PNG Salva come JPEG
Nome #
Bambini pretermine: nati per vivere 347
Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):2916-21. doi: 10.1073/pnas.1222577110. Epub 2013 Jan 28. Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. Zhao S1, Choi M, Overton JD, Bellone S, Roque DM, Cocco E, Guzzo F, English DP, Varughese J, Gasparrini S, Bortolomai I, Buza N, Hui P, Abu-Khalaf M, Ravaggi A, Bignotti E, Bandiera E, Romani C, Todeschini P, Tassi R, Zanotti L, Carrara L, Pecorelli S, Silasi DA, Ratner E, Azodi M, Schwartz PE, Rutherford TJ, Stiegler AL, Mane S, Boggon TJ, Schlessinger J, Lifton RP, Santin AD 315
Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients. 311
Prevalence of Chlamydia trachomatis and Neisseria gonorrhoeae infection in adolescents in Northern Italy: an observational school-based study. 298
Evaluation of a novel human IgG1 anti-claudin3 antibody that specifically recognizes its aberrantly localized antigen in ovarian cancer cells and that is suitable for selective drug delivery 265
OVEREXPRESSION OF CLOSTRIDIUM PERFRINGENS ENTEROTOXIN RECEPTORS CLAUDIN-3 AND CLAUDIN-4 IN UTERINE CARCINOSARCOMAS. 215
Correlation between serological immune response analyzed by a new ELISA for HPV-16/18 E7 oncoprotein and clinical characteristics of cervical cancer patients. 204
Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone 194
An Integrated Approach for a Structural and Functional Evaluation of Biosimilars: Implications for Erythropoietin 193
Cancer antigen 125, human epididymis 4, kallikrein 6, osteopontin and soluble mesothelin-related peptide immunocomplexed with immunoglobulin M in epithelial ovarian cancer diagnosis. 192
Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy. 188
Tissue factor expression in ovarian cancer: implications for immunotherapy with hI-con1, a factor VII-IgGF(c) chimeric protein targeting tissue factor 188
FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients 185
Secretoglobin expression in ovarian carcinoma: lipophilin B gene upregulation as an independent marker of better prognosis. 182
HER2/neu as a potential target for immunotherapy in gynecologic carcinosarcomas 181
Gene expression profile of ovarian serous papillary carcinomas: identification of metastasis-associated genes 179
Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma 176
Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients. 176
Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in retinoid-placebo trial in healthy women 174
Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody. 172
Mammaglobin B is an independent prognostic marker in epithelial ovarian cancer and its expression is associated with reduced risk of disease recurrence 172
2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). 171
A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. 168
Identification of optimal reference genes for gene expression normalization in a wide cohort of endometrioid endometrial carcinoma tissues. 168
Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management. 167
Trop-2 protein overexpression is an independent marker for predicting disease recurrence in endometrioid endometrial carcinoma 164
Overexpression of mammaglobin B in epithelial ovarian carcinomas. 163
Abridged republication of FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum 163
MAL gene overexpression as a marker of high-grade serous ovarian carcinoma stem-like cells that predicts chemoresistance and poor prognosis 163
DEVELOPMENT AND THERAPEUTIC EFFECT OF ADOPTIVELY TRANSFERRED T CELLS PRIMED BY TUMOR LYSATE-PULSED AUTOLOGOUS DENDRITIC CELLS IN A PATIENT WITH METASTATIC ENDOMETRIAL CANCER. 160
Consolidation therapies revisited: weekly paclitaxel 160
Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). 158
Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition 157
Chlamydia trachomatis genotypes in school adolescents, Italy 156
Uterine serous papillary carcinomas overexpress human trophoblast-cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized anti-Trop-2 monoclonal antibody 155
Mammaglobin B expression in human endometrial cancer 154
ADVANCES IN DENDRITIC-CELL-BASED THERAPEUTIC VACCINES FOR CERVICAL CANCER. 153
Trefoil factor 3: a novel serum marker identified by gene expression profiling in highgrade endometrial carcinomas 153
Development and characterization of a human single-chain antibody fragment against claudin-3: a novel therapeutic target in ovarian and uterine carcinomas. 153
Advanced Age and Medication Prescription: More Years, Less Medications? A Nationwide Report From the Italian Medicines Agency 153
Carcinoma of the Fallopian tube 153
Strategies to Improve Medication Adherence in Older Persons: Consensus Statement from the Senior Italia Federanziani Advisory Board 153
Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab. 152
HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities. 151
High-grade, chemotherapy-resistant primary ovarian carcinoma cell lines overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody 149
Racial differences in overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in Uterine Serous Papillary Cancer 148
TUMOR-INFILTRATING LYMPHOCYTES CONTAIN HIGHER NUMBERS OF TYPE 1 CYTOKINE EXPRESSORS AND DR+ T CELLS COMPARED WITH LYMPHOCYTES FROM TUMOR DRAINING LYMPH NODES AND PERIPHERAL BLOOD IN PATIENTS WITH CANCER OF THE UTERINE CERVIX. 147
Basic fibroblast growth factor in ovulatory cycle and postmenopausal human endometrium. 145
Computational and functional analysis of biopharmaceutical drugs in zebrafish: Erythropoietin as a test model 145
Follow-up after gastrectomy for cancer: the Charter Scaligero Consensus Conference 145
Eradication of chemotherapy-resistant CD44+ human ovarian cancer stem cells in mice by intraperitoneal administration of Clostridium perfringens enterotoxin. 144
Toward appropriate criteria in medication adherence assessment in older persons: Position Paper 144
Early stage cervical cancer: adjuvant treatment in negative lymph node cases. 141
Expression of tissue factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix: implications for immunotherapy with hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor 141
MiRNA landscape in stage I epithelial ovarian cancer defines the histotype specificities. 140
Carcinoma of the Fallopian tube 140
Prescription drug use among older adults in Italy: A country-wide perspective 139
Histological features of uteroplacental vessels in normal and hypertensive patients in relation to birthweight 138
Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer 138
Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2) 138
Prognostic Significance of Vascular Endothelial Growth Factor Serum Determination in Women with Ovarian Cancer 137
Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcome 137
Cervical carcinomas overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody 136
IN VITRO INDUCTION OF TUMOR-SPECIFIC HUMAN LYMPHOCYTE ANTIGEN CLASS I-RESTRICTED CD8 CYTOTOXIC T LYMPHOCYTES BY OVARIAN TUMOR ANTIGEN-PULSED AUTOLOGOUS DENDRITIC CELLS FROM PATIENTS WITH ADVANCED OVARIAN CANCER. 135
Differential in vitro sensitivity to patupilone versus paclitaxel in uterine and ovarian carcinosarcomas cell lines is linked to tubulin-beta-III expression. 135
Mental health and the global agenda. 134
Scaling up health knowledge at European level requires sharing integrated data: An approach for collection of database specification 134
INDUCTION OF OVARIAN TUMOR-SPECIFIC CD CYTOTOXIC T LYMPHOCYTES BY ACID-ELUTED PEPTIDE-PULSED AUTOLOGOUS DENDRITIC CELLS 133
Revised FIGO staging for carcinoma of the vulva, cervix, andendometrium. 133
Replacement therapy for breast cancer survivors. A pilot study 133
Early stage ovarian cancer: the Italian contribution to clinical research. An update 133
Gestational trophoblastic diseases 131
Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu. 130
Carcinoma of the corpus uteri 130
Time to face the challenge of multimorbidity. A European perspective from the joint action on chronic diseases and promoting healthy ageing across the life cycle (JA-CHRODIS) 130
High prevalence of poor quality drug prescribing in older individuals: a nationwide report from the Italian Medicines Agency (AIFA) 129
INCREASED LEVELS OF INTERLEUKIN-10 AND TRANSFORMING GROWTH FACTOR-BETA IN THE PLASMA AND ASCITIC FLUID OF PATIENTS WITH ADVANCED OVARIAN CANCER. 128
Hearing loss and cognitive decline in older adults: Questions and answers 128
HPV vaccination acceptability in young boys 127
History of the FIGO cancer staging system 126
Claudin-7 expression in human epithelial ovarian cancer 126
Staging classification for cancer of the ovary, fallopian tube, and peritoneum 126
Neoadjuvant chemotherapy in the treatment of locally advanced cervical carcinoma in pregnancy 125
Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial. 125
High-grade, chemotherapy-resistant ovarian carcinomas overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody. 125
Interventional tools to improve medication adherence: Review of literature 125
Carcinoma of the fallopian tube. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. 124
Pattern of failure and value of follow-up procedures in endometrial and cervical cancer patients. 124
Carcinoma of the corpus uteri 124
Carcinoma of the ovary. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. 123
New development of the FIGO staging system. 122
Hormone replacement therapy in breast cancer 122
Interval debulking surgery in advanced epithelial ovarian cancer 121
Carcinoma of the corpus uteri. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. 120
Systemic therapy for gynecological neoplasms: ovary, cervix and endometrium 120
Gestational trophoblastic diseases 120
Overexpression of kallikrein 10 (hK10) in uterine serous papillary carcinomas. 119
PHENOTYPIC AND FUNCTIONAL ANALYSIS OF TUMOR-INFILTRATING LYMPHOCYTES COMPARED WITH TUMOR-ASSOCIATED LYMPHOCYTES FROM ASCITIC FLUID AND PERIPHERAL BLOOD LYMPHOCYTES IN PATIENTS WITH ADVANCED OVARIAN CANCER. 119
Systemic therapy for gynecological neoplasms: ovary, cervix, and endometrium. 119
Optimizing gemcitabine regimens in ovarian cancer. 118
Totale 15.523
Salva come PNG Salva come JPEG
Categoria #
all - tutte 100.491
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 100.491
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.771 0 0 0 0 0 334 135 323 360 263 271 85
2021/20221.537 124 236 13 71 11 106 77 88 77 292 123 319
2022/20231.190 240 30 50 69 83 343 10 94 153 11 52 55
2023/20241.512 78 35 145 108 82 358 49 60 330 57 20 190
2024/20252.699 19 31 10 379 308 265 188 77 264 165 622 371
2025/20263.813 674 835 421 1.007 610 266 0 0 0 0 0 0
Totale 24.193